Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809448 | 0.91 | ACHE (0.47) | ACHEAPPBCHETLR7GAA | |
| SCHEMBL2812214 | 0.89 | ADORA2A (0.42) | APPSMN1; SMN2GAASIGMAR1 | |
| SCHEMBL537584 | 0.88 | ACHE (0.45) | ACHEAPPTLR7SIGMAR1BACE1 | |
| SCHEMBL2812972 | 0.88 | SIGMAR1 (0.38) | ACHETLR7SIGMAR1BACE1 | |
| SCHEMBL2811945 | 0.87 | ACHE (0.38) | ACHECYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL2812302 | 0.84 | ACHE (0.37) | ACHECYP3A4CYP2D6SMN1; SMN2BACE1 | |
| SCHEMBL2813066 | 0.84 | ACHE (0.38) | ACHETLR7GAABACE1 | |
| SCHEMBL2813048 | 0.83 | IP6K1 (0.40) | SIGMAR1 | |
| SCHEMBL2816411 | 0.82 | ACHE (0.47) | ACHECYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2813941 | 0.82 | ADORA3 (0.41) | ACHECYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | ACHE 4402/4885APP 3167/4885CYP1A2 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.